(Total Views: 423)
Posted On: 11/18/2019 8:13:32 AM
Post# of 154754
They are gettinh serious 
LifeSci to develop and execute comprehensive corporate communications and public relations programs
VANCOUVER, Wash., Nov. 18, 2019 (GLOBE NEWSWIRE)
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that it has engaged LifeSci Public Relations (“LifeSci”) to increase awareness of the Company’s brand, science and clinical programs.
“This is the perfect time to collaborate with LifeSci to help inform the public and the investment community about the power of leronlimab as we prepare to file our first Biologics License Application (BLA),” said Dr. Nader Pourhassan, president and chief executive officer of CytoDyn. “LifeSci’s expertise in corporate communications and public relations, supported by their extensive experience in capital markets and scientific research, make them an ideal partner for our company at this important juncture in our evolution.”
LifeSci is a leading provider of strategic consulting services in the areas of investor relations, public relations, corporate communications, executive search and capital markets advisory. LifeSci Public Relations will provide CytoDyn with integrated communications services through strategic messaging, media outreach, and social and digital media efforts.
LifeSci to develop and execute comprehensive corporate communications and public relations programs
VANCOUVER, Wash., Nov. 18, 2019 (GLOBE NEWSWIRE)
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that it has engaged LifeSci Public Relations (“LifeSci”) to increase awareness of the Company’s brand, science and clinical programs. “This is the perfect time to collaborate with LifeSci to help inform the public and the investment community about the power of leronlimab as we prepare to file our first Biologics License Application (BLA),” said Dr. Nader Pourhassan, president and chief executive officer of CytoDyn. “LifeSci’s expertise in corporate communications and public relations, supported by their extensive experience in capital markets and scientific research, make them an ideal partner for our company at this important juncture in our evolution.”
LifeSci is a leading provider of strategic consulting services in the areas of investor relations, public relations, corporate communications, executive search and capital markets advisory. LifeSci Public Relations will provide CytoDyn with integrated communications services through strategic messaging, media outreach, and social and digital media efforts.
(2)
(0)
